12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MK-3475: Phase II started

Merck disclosed in its 4Q12 earnings that it began a double-blind Phase II trial to compare 2 doses of IV MK-3475 vs. investigator-choice chemotherapy regimens of carboplatin, paclitaxel,...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >